{"nctId":"NCT02886702","briefTitle":"A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis","startDateStruct":{"date":"2016-09-19","type":"ACTUAL"},"conditions":["Plaque Psoriasis"],"count":855,"armGroups":[{"label":"Test","type":"EXPERIMENTAL","interventionNames":["Drug: Tazarotene Cream 0.05%"]},{"label":"Reference","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TAZORAC® (tazarotene) Cream 0.05%"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tazarotene Cream 0.05%","otherNames":["Tazarotene"]},{"name":"TAZORAC® (tazarotene) Cream 0.05%","otherNames":["Tazarotene"]},{"name":"Placebo","otherNames":["Vehicle"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a definite clinical diagnosis of stable (at least 6 months) plaque psoriasis, involving at least 2% and no more than 20% of the body surface area (BSA) (not including the scalp and intertriginous areas)\n* Have a minimum plaque elevation at the target lesion site of at least moderate severity (grade ≥ 3 on the Psoriasis Area Severity Index \\[PASI\\]). The most severe lesion at baseline should be identified as the target lesion\n* Have an Investigator's Global Assessment (IGA) of disease severity of at least moderate (score ≥ 3) as an overall assessment of all lesions to be treated.\n\nExclusion Criteria:\n\n* A female subject who is pregnant, nursing, planning a pregnancy, or does not agree to use an acceptable form of birth control within the study participation period\n* Have a current diagnosis of unstable forms of psoriasis in the treatment area, including pustular, guttate, exfoliative or erythrodermic psoriasis\n* Have a history of psoriasis unresponsive to topical treatments","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment Success Assessed by IGA","description":"Proportion of subjects with treatment success (defined as none, minimal or mild disease, a score of 0, 1 or 2 within the treatment area) on the \"Investigator's Global Assessment of Disease Severity\" (IGA) at the Week 12 visit (Day 85 ± 4 days, End of Study).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.8","spread":null},{"groupId":"OG001","value":"63.2","spread":null},{"groupId":"OG002","value":"56.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Severity None or Minimal on IGA","description":"Proportion of subjects with none or minimal disease, a score of 0 or 1 on the IGA at the Week 12 visit (Day 85 ± 4 days, End of Study).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"22.6","spread":null},{"groupId":"OG002","value":"16.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Target Site Plaque Elevation, Scaling and Erythema Scores of Less Than or Equal to 1 on the PASI","description":"Proportion of subjects with target site plaque elevation, scaling and erythema scores of less than or equal to 1 (Clear or Almost Clear) on the Psoriasis Area Severity Index (PASI) at the Week 12 visit (Day 85 ± 4 days, End of Study).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"22.2","spread":null},{"groupId":"OG002","value":"16.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":284},"commonTop":["Application site pain","Application site pruritus","Application site erosion","Application site erythema","Headache"]}}}